Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Open-label, Multi-center Phase I Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies

NCT07532746 is registered in ClinicalTrials.gov with Kousai Bio Co., Ltd. as lead sponsor.

NCT NCT07532746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07532746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Open-label, Multi-center Phase I Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Lead sponsor
Kousai Bio Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 1, 2026
Completion date
December 31, 2029
Enrollment
55 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory ebv-associated hematological malignancies